MNN9 Antibody

What is MNN9 and why is it important in research?

MNN9 is a conserved glycosyltransferase that forms part of the Golgi-located M-Pol I complex in fungi, particularly in Saccharomyces cerevisiae and Candida albicans. It functions as both a priming glycosyltransferase and an allosteric activator, playing a crucial role in the mannan biosynthesis pathway of the fungal cell wall . MNN9 is particularly important in research because knockouts of this gene show an aberrant cell wall structure and increased antibiotic sensitivity, suggesting its potential as a drug target . Additionally, MNN9 appears to modulate host immune responses, making it relevant for immunological and pathogenesis studies .

How does MNN9 function in cellular biochemistry?

MNN9 functions as an α-1,6-mannosyltransferase that initiates the formation of the mannose backbone in fungal cell walls. The enzyme works in complex with Van1p as part of the M-Pol I complex in the Golgi apparatus . Structurally, MNN9 has a GT-62 family fold with a unique extension compared to related glycosyltransferases. It requires manganese (Mn²⁺) as a cofactor and uses GDP-mannose as the sugar donor to transfer mannose to acceptor substrates . The enzymatic activity involves conserved amino acid residues, particularly R209, which lines the mannose binding site and is essential for the enzyme's activity .

What types of MNN9 antibodies are available for research?

Research-grade MNN9 antibodies are available in several formats:

Note: Specificity testing should be performed for cross-reactivity with MNN9 from different fungal species depending on the research focus .

How can I detect MNN9 expression in fungal samples?

For detecting MNN9 expression in fungal samples, Western blotting provides the most reliable results. The procedure should include:

• Sample preparation: Lyse fungal cells using glass beads or enzymatic methods to disrupt the cell wall

• Protein extraction: Use a buffer containing detergents (0.5% Triton X-100) and protease inhibitors

• Gel electrophoresis: Separate proteins on 10-12% SDS-PAGE

• Transfer and blotting: Transfer to PVDF membrane and block with 5% BSA

• Primary antibody: Incubate with MNN9-specific antibody (1:500-1:1000 dilution)

• Secondary antibody: Use species-appropriate HRP-conjugated antibody

• Detection: Develop using chemiluminescence

For immunofluorescence microscopy, co-localization with Golgi markers helps confirm proper localization, as MNN9 is predominantly found in the Golgi apparatus .

What are the optimal conditions for MNN9 antibody immunoprecipitation experiments?

For successful immunoprecipitation of MNN9:

• Cell lysis: Use a mild non-denaturing lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.4, 1% NP-40) with protease inhibitors

• Pre-clearing: Incubate lysate with protein A/G beads to reduce non-specific binding

• Antibody binding: Add 2-5 μg of MNN9 antibody per 500 μg of protein lysate

• Incubation: Rotate overnight at 4°C

• Bead capture: Add protein A/G beads and incubate for 2-4 hours

• Washing: Perform 4-5 washes with decreasing salt concentration

• Elution: Use either acidic elution (pH 2.5) or SDS sample buffer

When co-immunoprecipitating MNN9 with Van1p or other M-Pol I complex components, gentler lysis conditions may be required to maintain complex integrity .

How can I assess MNN9 enzyme activity in research samples?

A novel coupled enzyme assay can be used to assess MNN9 enzymatic activity:

• Prepare reaction mixture containing:

  • Purified MNN9 protein or cell extract

  • 10 mM MnCl₂ (as cofactor)

  • GDP-mannose (sugar donor)

  • α-1,6-linked mannobiose (acceptor substrate)

  • Buffer (50 mM HEPES, pH 7.2)

• Use α-1,6-mannosidase from Bacillus subtilis TN-31 (Aman6) as a coupling enzyme that can detect newly formed mannotriose

• For detection, use fluorophore-assisted carbohydrate gel electrophoresis (FACE) or the 4-methylumbelliferone (4-MU) fluorescence-based assay

This method allows for quantitative assessment of MNN9 activity through steady-state kinetics measurements.

How can MNN9 antibodies be used to study fungal cell wall biogenesis?

For studying fungal cell wall biogenesis with MNN9 antibodies:

• Temporal monitoring: Use time-course immunofluorescence microscopy with MNN9 antibodies to track Golgi localization during cell wall formation

• Co-localization studies: Combine MNN9 antibodies with markers for different glycosylation stages to map the mannan synthesis pathway

• Pulse-chase experiments: Use MNN9 antibodies to immunoprecipitate newly synthesized versus mature complexes

• Structural studies: Combine with high-resolution microscopy (STORM, PALM) to visualize M-Pol I complex organization

• Mutant analysis: Compare wild-type versus mutant strains to correlate structural changes with functional outcomes in cell wall architecture

The research should include controls with mnn9 knockout strains to confirm antibody specificity.

How does MNN9 influence host-pathogen interactions in Candida infections?

MNN9 plays a significant role in modulating host immune responses during Candida infections:

• Cytokine profiles: The deletion of MNN9 in C. albicans induces stronger inflammatory cytokine releases (particularly IL-1α and IL-1β) from epithelial cells without altering damage potential

• Cell adhesion: MNN9 mutants show reduced adhesion to hepatic cells and decreased invasiveness in multiple cell lines, suggesting MNN9's involvement in host-cell attachment mechanisms

• MAPK signaling: Infection with MNN9 mutants results in altered activation of MKP1, ERK1/2, and JNK signaling pathways in epithelial cells, with delayed but prolonged activation

• Virulence modulation: In mouse models of disseminated candidiasis, MNN9 mutants show significantly reduced virulence, highlighting the importance of proper mannosylation for pathogenicity

Antibodies against MNN9 can be used to study these interactions through immunofluorescence co-localization, immune complex isolation, and receptor binding assays.

What approaches can be used to conjugate MNN9 antibodies to nanoparticles for enhanced detection?

For conjugating MNN9 antibodies to magnetic nanoparticles:

• Surface activation: Treat magnetic nanoparticles with carbodiimide chemistry (EDC/NHS) to create reactive groups

• Antibody preparation: Purify and buffer-exchange antibodies into coupling buffer (MES buffer, pH 6.0)

• Conjugation reaction: Mix activated nanoparticles with antibodies at optimal ratio (typically 10-20 μg antibody per mg of particles)

• Blocking: Block unreacted sites with BSA or ethanolamine

• Characterization: Assess conjugation efficiency using:

  • High-resolution CE-single strand conformational polymorphism

  • Stuffer-free multiplex ligation-dependent probe amplification system

• Functionality testing: Test capturing ability using known MNN9-expressing strains versus knockout controls

The characterization should include stability assessment under different storage conditions to ensure reproducible performance in pathogen detection applications.

Why might MNN9 antibodies show cross-reactivity with other mannosyltransferases?

Cross-reactivity of MNN9 antibodies with other mannosyltransferases can occur due to:

• Structural homology: MNN9 belongs to the GT-62 family that shares conserved domains with other glycosyltransferases, particularly within the catalytic core (amino acids 93-395 in S. cerevisiae MNN9)

• Epitope similarity: The DXD catalytic motif and GDP-binding site are highly conserved across different mannosyltransferases

• Complex formation: MNN9 forms complexes with other proteins like Van1p, potentially leading to co-immunoprecipitation and false positive results

To minimize cross-reactivity:

• Use antibodies raised against unique regions of MNN9 rather than conserved domains

• Validate with knockout controls (mnn9 deletion strains)

• Perform competitive binding assays with purified related enzymes

• Use western blotting to confirm detection of the correct molecular weight band (approximately 45-50 kDa for the glycosyltransferase core)

How can I distinguish between active and inactive forms of MNN9 in my experiments?

Distinguishing active from inactive MNN9 requires multiple approaches:

• Activity-based probes: Develop GDP-mannose analogs that covalently bind only to catalytically active MNN9

• Conformational antibodies: Use antibodies that specifically recognize the active conformation (Mn²⁺ and GDP-bound state)

• Phosphorylation status: Check for post-translational modifications that might regulate activity

• Complex formation analysis: Active MNN9 usually exists in complex with Van1p; co-immunoprecipitation can assess complex integrity

• Direct activity assay: Use the mannosyltransferase assay with fluorophore-assisted carbohydrate gel electrophoresis (FACE) to directly measure enzymatic activity

Mutations in key catalytic residues (such as R209A or D236N) can serve as negative controls for activity assays while retaining antibody recognition.

What controls should I include when studying MNN9 in different fungal species?

When studying MNN9 across different fungal species, include these controls:

• Species-specific knockout strains: Generate or obtain mnn9 deletion mutants for each species under study

• Complementation controls: Re-introduce the MNN9 gene to verify phenotype rescue

• Sequence alignment validation: Confirm epitope conservation across species for the antibody in use

• Cross-species reactivity testing:

• Functional assays: Compare mannan composition using specific stains or lectins to correlate antibody detection with functional outcomes

• Cell wall phenotyping: Assess sensitivity to cell wall stressors (Congo Red, Calcofluor White) to confirm functional homology

Proper controls ensure that observed differences reflect true biological variation rather than technical limitations of the antibodies used.

How might MNN9 antibodies be used in developing antifungal therapeutics?

MNN9 antibodies could contribute to antifungal therapeutic development through:

• Target validation: Confirming MNN9's essential role in fungal cell wall integrity across different pathogenic species

• High-throughput screening: Developing competition assays using labeled MNN9 antibodies to identify small molecule inhibitors

• Structural studies: Using antibody-MNN9 co-crystallization to identify key binding epitopes for rational drug design

• Immunotherapeutic approaches: Developing antibody-drug conjugates that specifically target fungal cells

• Diagnostic applications: Creating rapid detection systems for fungal infections based on MNN9 detection

The potential of MNN9 as a drug target is supported by findings that mnn9 knockouts show increased antibiotic sensitivity and reduced virulence in infection models .

What novel approaches might improve MNN9 antibody specificity and sensitivity?

Improving MNN9 antibody specificity and sensitivity could be achieved through:

• Epitope mapping: Identifying unique, surface-exposed regions of MNN9 that differ from related mannosyltransferases

• Recombinant antibody engineering: Creating single-chain variable fragments (scFvs) or nanobodies with enhanced specificity

• Affinity maturation: Using directed evolution or computational design to increase binding affinity

• Signal amplification methods: Developing proximity ligation assays that require dual epitope recognition

• Conformation-specific antibodies: Generating antibodies that specifically recognize the active GDP-Mn²⁺-bound conformation

These approaches would be particularly valuable for distinguishing between closely related mannosyltransferases in complex fungal samples.